Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676118 | 0.95 | SYK (0.48) | SYK | |
| SCHEMBL31676085 | 0.95 | SYK (0.48) | SYK | |
| SCHEMBL31676300 | 0.90 | SYK (0.49) | SYK | |
| SCHEMBL31676357 | 0.90 | SYK (0.46) | SYK | |
| SCHEMBL30613622 | 0.90 | SYK (0.46) | SYK | |
| SCHEMBL31676135 | 0.89 | SYK (0.46) | SYK | |
| SCHEMBL31676032 | 0.88 | SYK (0.57) | SYKJAK1ZAP70BTKLRRK2 | |
| SCHEMBL31676439 | 0.88 | SYK (0.57) | SYKJAK1ZAP70BTKLRRK2 | |
| SCHEMBL31676499 | 0.88 | SYK (0.57) | SYKJAK1ZAP70BTKLRRK2 | |
| SCHEMBL31676401 | 0.88 | SYK (0.44) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | SYK 3/4885JAK1 17/4885ZAP70 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.